EU cosmetics regulation
This article was originally published in The Rose Sheet
Executive Summary
Seventh Amendment to the Cosmetics Directive "provides an opportunity for proactive corporations to move ahead with new products and gain a market share in a global economy," according to a Citizens Advisers, Inc. report examining the impact of EU cosmetics regulations. Conversely, companies that do not reformulate to meet EU standards "could face reduced market demand, potential liabilities and damaged reputation," financial firm asserts. In light of recent publicity surrounding potentially harmful cosmetic ingredients, U.S. consumers are likely to "demand the same level of safety as Europeans," report adds. The Seventh Amendment, adopted in 2003, calls for a phased-in ban on animal testing for cosmetics and restricts the use of substances that have been found to be carcinogenic, mutagenic or reproductive toxins (1"The Rose Sheet" Feb. 17, 2003, In Brief)...
You may also be interested in...
EU animal testing
Council of Ministers adopts Seventh Amendment to the Cosmetics Directive banning animal testing on cosmetics. Legislation, passed during the Council's Jan. 27-28 meeting, is in line with joint text agreed upon in conciliation with European Parliament, which passed the amendment Jan. 15. Long-debated marketing/testing ban passed conciliation in November prohibiting testing of cosmetics on animals immediately when alternative methods are available and imposing a six-year deadline for most tests when validated alternatives are not yet available (1"The Rose Sheet" Nov. 25, 2002, p. 6)...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.